А-86929

А-86929
Називи
	IUPAC назив 9,10-Dihidroksi-2-propil-4,5,5a(R),6,7,11b(S)-heksahidrobenzo[f]tieno[2,3-c]hinolin
Идентификација
CAS број	166591-11-3 ;
3Д модел (Jmol)	интерактивна слика;
ChemSpider	8017113 ;
PubChem C ID	9841398;
	SMILES Oc1cc3c(cc1O)CCC4C3c2cc(CCC)sc2CN4; ; ; ; ; ;
Својства
Хемијска формула	C18H21NO2S
Моларна маса	315,429 g/mol
	Уколико није другачије напоменуто, подаци се односе на стандардно стање материјала (на 25 °C [77 °F], 100 kPa).
	верификуј (шта је ?)
	Референце инфокутије

А-86929 је синтетичко једињење које делује као селективни агонист допаминског рецептора D₁.^[3]^[4] Он је развијен као могући треатмент за Паркинсонову болест,^[5] као и за друге примене, попут кокаинске адикције.^[6]^[7] Он има релативно добру ефикасност на људима, међутим узрокује дискинезије, те је његов развој прекинут.^[8]^[9] Он је углавном кориштен у облику диацетатног естра, пролека адроголид (ABT-431), koji ima bolju biodostupnost.^[10]^[11]

Reference[уреди | уреди извор]

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Michaelides MR, Hong Y, DiDomenico S, Asin KE, Britton DR, Lin CW, Williams M, Shiosaki K (1995). „(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431)”. Journal of Medicinal Chemistry. 38 (18): 3445—7. PMID 7658429. doi:10.1021/jm00018a002.
^ Ehrlich PP, Ralston JW, Michaelides MR (1997). „An Efficient Enantioselective Synthesis of the D1 Agonist (5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia- 5-azacyclopenta[c]phenanthrene-9,10-diol (A-86929)”. The Journal of Organic Chemistry. 62 (9): 2782—2785. PMID 11671640. doi:10.1021/jo970066l.
^ Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S, Carter JH, Nutt JG (1999). „ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease”. Annals of Neurology. 45 (6): 736—41. PMID 10360765. doi:10.1002/1531-8249(199906)45:6<736::AID-ANA7>3.0.CO;2-F.
^ Haney M, Collins ED, Ward AS, Foltin RW, Fischman MW (1999). „Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans”. Psychopharmacology. 143 (1): 102—10. PMID 10227086. doi:10.1007/s002130050925.
^ Gorelick DA, Gardner EL, Xi ZX (2004). „Agents in development for the management of cocaine abuse”. Drugs. 64 (14): 1547—73. PMID 15233592. doi:10.2165/00003495-200464140-00004.
^ Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WW, Wright S (2001). „Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease”. Archives of Neurology. 58 (2): 249—54. PMID 11176963. doi:10.1001/archneur.58.2.249.
^ Zhang J, Xiong B, Zhen X, Zhang A (2009). „Dopamine D1 receptor ligands: where are we now and where are we going”. Medicinal Research Reviews. 29 (2): 272—94. PMID 18642350. doi:10.1002/med.20130.
^ Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M (1996). „ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 276 (1): 150—60. PMID 8558425.
^ Giardina WJ, Williams M (2001). „Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data”. CNS Drug Reviews. 7 (3): 305—16. PMID 11607045. doi:10.1111/j.1527-3458.2001.tb00201.x.

Молимо Вас, обратите пажњу на важно упозорење
у вези са темама из области медицине (здравља).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[pmid7658429-3] Michaelides MR, Hong Y, DiDomenico S, Asin KE, Britton DR, Lin CW, Williams M, Shiosaki K (1995). „(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431)”. Journal of Medicinal Chemistry. 38 (18): 3445—7. PMID 7658429. doi:10.1021/jm00018a002.

[pmid11671640-4] Ehrlich PP, Ralston JW, Michaelides MR (1997). „An Efficient Enantioselective Synthesis of the D1 Agonist (5aR,11bS)-4,5,5a,6,7,11b-Hexahydro-2-propyl-3-thia- 5-azacyclopenta[c]phenanthrene-9,10-diol (A-86929)”. The Journal of Organic Chemistry. 62 (9): 2782—2785. PMID 11671640. doi:10.1021/jo970066l.

[pmid10360765-5] Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S, Carter JH, Nutt JG (1999). „ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease”. Annals of Neurology. 45 (6): 736—41. PMID 10360765. doi:10.1002/1531-8249(199906)45:6<736::AID-ANA7>3.0.CO;2-F.

[pmid10227086-6] Haney M, Collins ED, Ward AS, Foltin RW, Fischman MW (1999). „Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans”. Psychopharmacology. 143 (1): 102—10. PMID 10227086. doi:10.1007/s002130050925.

[pmid15233592-7] Gorelick DA, Gardner EL, Xi ZX (2004). „Agents in development for the management of cocaine abuse”. Drugs. 64 (14): 1547—73. PMID 15233592. doi:10.2165/00003495-200464140-00004.

[pmid11176963-8] Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C, Carter JH, Currie LJ, Fabre N, Thalamas C, Giardina WW, Wright S (2001). „Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease”. Archives of Neurology. 58 (2): 249—54. PMID 11176963. doi:10.1001/archneur.58.2.249.

[pmid18642350-9] Zhang J, Xiong B, Zhen X, Zhang A (2009). „Dopamine D1 receptor ligands: where are we now and where are we going”. Medicinal Research Reviews. 29 (2): 272—94. PMID 18642350. doi:10.1002/med.20130.

[pmid8558425-10] Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M (1996). „ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 276 (1): 150—60. PMID 8558425.

[pmid11607045-11] Giardina WJ, Williams M (2001). „Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data”. CNS Drug Reviews. 7 (3): 305—16. PMID 11607045. doi:10.1111/j.1527-3458.2001.tb00201.x.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]